Imikhiqizo

Izidakamizwa ze-fluorouracil antineoplastic ziyizidakamizwa ze-fluorouracil.I-thymidine phosphorylase ekhona kuzicubu zesimila isebenza kuyo ukuze iguqule ibe yi-fluorochemicalbook uracil esimila, ngaleyo ndlela isebenzise umphumela wokulwa nesimila.Ukucaciswa kwayo okulwa nesimila kunamandla, futhi ubuthi bayo buphansi.Emtholampilo esetshenziselwa umdlavuza wesisu, umdlavuza we-colorectal, umdlavuza webele, izinga lokukhululwa lingafinyelela ngaphezu kwama-30%.

Ukusebenza kwe-systemic chemotherapy ekusakazeni kwe-peritoneal umdlavuza wesisu akukacaci.Ukusebenza kwe-paclitaxel yamasonto onke kuhlanganiswe ne-doxifluridine (5'-DFUR) ezigulini ezinomdlavuza wesisu ezine-ascites ezimbi.Ukwelashwa kwakuhlanganisa i-paclitaxel nge-intravenously (iv) elawulwa ku-80 mg/m(2) ngezinsuku ezingu-1, 8 kanye ne-15 njalo emavikini angu-4, futhi i-doxifluridine ilawulwa ngomlomo ku-533 mg/m(2) ngezinsuku ezingu-1-5 masonto onke.Izinga lokuphendula leziguli ezine-ascites lanqunywa ngokusekelwe ku-Japanese Classification of Gastric Carcinoma.Futhi, ukuhlushwa kwe-paclitaxel ku-ascites kukalwa.Iziguli ezingamashumi amabili nane zaphenywa.Izinga lokuphendula (RR) lalingu-41.7%, okuhlanganisa ukukhululwa okuphelele (CR) nokukhululwa okuyingxenye (PR) ezigulini ezi-4 nezi-6, ngokulandelanayo.Ukugxila kwe-paclitaxel ku-ascites kwagcinwa phakathi kuka-0.01 μM no-0.05 μM kuze kube amahora angu-72.Ukusinda okuphelele kwe-median (OS) kwakuyizinsuku ezingu-215, futhi izinga lokusinda lonyaka ongu-1 lalingu-29.2%.Abukho ubuthi obunzima obaphawuliwe.I-paclitaxel yamasonto onke ihlanganiswe ne-doxifluridine iyasebenza ezigulini ezinomdlavuza wesisu ezinama-ascites ayingozi anephrofayili yobuthi eyamukelekayo.